Johnson D H
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn.
Chest. 1993 Apr;103(4 Suppl):423S-426S. doi: 10.1378/chest.103.4_supplement.423s.
The identification of new agents active against small-cell lung cancer (SCLC) remains a high priority for clinical investigators. Recently, 2 very different approaches have been used to evaluate new agents in this disease. Some groups have opted to test new agents in previously untreated patients with extensive-stage SCLC, and the second approach is to continue to test new agents only in previously treated patients. Regardless of which method is used, it appears that new-agent activity can be assessed in either previously treated or untreated SCLC patients without compromising the therapeutic gains of the past 2 decades, provided proper patient selection guidelines are employed.
